
Align Technology ALGN
$ 178.59
7.02%
Quarterly report 2025-Q3
added 11-05-2025
Align Technology Deferred Revenue 2011-2026 | ALGN
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Align Technology
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.33 B | 1.43 B | 1.34 B | 1.15 B | 778 M | 564 M | 406 M | 267 M | 191 M | 130 M | 90.7 M | 77.3 M | 62 M | 52.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.43 B | 52.3 M | 562 M |
Quarterly Deferred Revenue Align Technology
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 1.32 B | 1.32 B | 1.33 B | 1.38 B | 1.38 B | 1.41 B | 1.43 B | 1.41 B | 1.4 B | 1.38 B | 1.34 B | 1.29 B | - | 1.21 B | 1.15 B | 1.07 B | 976 M | 863 M | 778 M | 778 M | 778 M | 778 M | 564 M | 564 M | 564 M | 564 M | 393 M | 393 M | 393 M | 393 M | 268 M | 268 M | 268 M | 268 M | 191 M | 191 M | 191 M | 191 M | 130 M | 130 M | 130 M | 130 M | 90.7 M | 90.7 M | 90.7 M | 90.7 M | 77.3 M | 77.3 M | 77.3 M | 77.3 M | 62 M | 62 M | 62 M | 62 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.43 B | 52.3 M | 575 M |
Deferred Revenue of other stocks in the Medical devices industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AxoGen
AXGN
|
14 K | $ 32.67 | 5.42 % | $ 1.5 B | ||
|
Conformis
CFMS
|
215 K | - | - | $ 16.4 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
508 K | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
401 K | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
59.8 M | $ 12.24 | 2.47 % | $ 1.65 B | ||
|
Cardiovascular Systems
CSII
|
2.11 M | - | 0.15 % | $ 844 M | ||
|
Allied Healthcare Products
AHPI
|
563 K | - | 3.58 % | $ 2.21 M | ||
|
ClearPoint Neuro
CLPT
|
1.67 M | $ 9.36 | 3.2 % | $ 265 M | ||
|
Dynatronics Corporation
DYNT
|
150 K | - | 14.99 % | $ 929 K | ||
|
Obalon Therapeutics, Inc.
OBLN
|
424 K | - | -5.86 % | $ 30.6 M | ||
|
Bruker Corporation
BRKR
|
438 M | $ 38.24 | 4.28 % | $ 5.7 K | ||
|
Second Sight Medical Products
EYES
|
335 K | - | -0.97 % | $ 54.4 M | ||
|
Apollo Endosurgery
APEN
|
88 K | - | - | $ 475 M | ||
|
FONAR Corporation
FONR
|
4.29 M | $ 18.61 | 0.13 % | $ 122 M | ||
|
Globus Medical
GMED
|
27.7 M | $ 91.72 | 1.91 % | $ 12.4 B | ||
|
EDAP TMS S.A.
EDAP
|
4.05 M | $ 3.34 | -1.82 % | $ 125 M | ||
|
CryoLife, Inc.
CRY
|
1.45 M | - | -4.14 % | $ 702 M | ||
|
Helius Medical Technologies
HSDT
|
148 K | $ 1.89 | 3.28 % | $ 1.15 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
10.5 M | $ 9.62 | 3.11 % | $ 741 M | ||
|
Invacare Corporation
IVC
|
2.28 M | - | - | $ 24.7 M | ||
|
Integer Holdings Corporation
ITGR
|
5.21 M | $ 87.43 | 2.73 % | $ 3.04 B | ||
|
Aziyo Biologics
AZYO
|
533 K | - | 1.37 % | $ 20.5 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
33 | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
732 K | - | 0.03 % | $ 1.58 B | ||
|
LivaNova PLC
LIVN
|
11.5 M | $ 64.67 | 1.78 % | $ 3.53 B | ||
|
Misonix, Inc.
MSON
|
13.3 K | - | - | $ 462 M | ||
|
LENSAR
LNSR
|
2.6 M | $ 5.67 | 0.71 % | $ 67.8 M | ||
|
Medtronic PLC
MDT
|
315 M | $ 88.04 | 1.87 % | $ 113 B | ||
|
Butterfly Network
BFLY
|
16.1 M | $ 4.18 | 3.21 % | $ 885 M | ||
|
Myomo
MYO
|
2.51 K | $ 0.68 | -0.3 % | $ 28.5 M | ||
|
Intersect ENT, Inc.
XENT
|
137 K | - | - | $ 955 M | ||
|
Cytosorbents Corporation
CTSO
|
182 K | $ 0.64 | 4.94 % | $ 39.8 M | ||
|
BIOLASE
BIOL
|
2.45 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
170 K | $ 9.84 | 1.76 % | $ 352 M | ||
|
BioSig Technologies
BSGM
|
16 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
313 M | $ 62.3 | 0.71 % | $ 92.2 B | ||
|
Alphatec Holdings
ATEC
|
10.4 M | $ 11.45 | 3.76 % | $ 1.72 B | ||
|
IRIDEX Corporation
IRIX
|
2.16 M | $ 1.14 | 10.68 % | $ 19.3 M |